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Toxoplasma gondii has been suggested as an important opportunistic pathogen
in immunocompromised patients. We conducted a global meta-analysis to assess
the prevalence and odds ratios (ORs) of T. gondii infection in immunocompromised
individuals. Electronic databases were reviewed for T. gondii infection in HIV/AIDS
patients, cancer patients, and transplant recipients, and meta-analyses were conducted
to calculate overall estimated prevalence and ORs using random or fixed-effects
models. Totally, 72 eligible studies were included. The estimated pooled prevalence
of T. gondii infection in immunocompromised patients and the control was 35.9 and
24.7% (p < 0.001), with an OR of 2.24, i.e., 42.1 and 32.0% for HIV/AIDS patients
and the control (p < 0.05), 26.0 and 12.1% for cancer patients and the control (p <
0.001), and 42.1 and 34.5% for transplant recipients and the control (p > 0.05), whose
estimated pooled ORs were 1.92 (95% CI, 1.44–2.55), 2.89 (95% CI, 2.36–3.55), and
1.51 (95% CI, 1.16–1.95), respectively. This study is the first to demonstrate that the
immunocompromised patients are associated with higher odds of T. gondii infection,
and appropriate prevention and control measures are highly recommended for these
susceptible populations.
Keywords: Toxoplasma gondii, immunocompromised patients, HIV/AIDS patients, cancer patients, transplant
recipients, prevalence, odds ratio
INTRODUCTION
The protozoan parasite Toxoplasma gondii can infect nearly all warm-blooded animals, including
humans (Robert-Gangneux and Darde, 2012; Liu et al., 2015). Approximately 30% of the world’s
population is estimated to be infected with T. gondii (Montoya and Liesenfeld, 2004). Humans
become primarily infected by ingesting raw or undercooked meat containing viable tissue cysts,
or by ingesting water or food contaminated with oocysts from infected cat feces (Baldursson and
Karanis, 2011; Meireles et al., 2015). In healthy humans, the infection with T. gondii is usually
asymptomatic, but it can be fatal in the immunocompromised individuals, such as HIV/AIDS
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patients, cancer patients, and organ transplant recipients (Da
Cunha et al., 1994; Pott and Castelo, 2013; Agrawal et al., 2014;
Lu et al., 2015).
Toxoplasmosis of immunosuppressed individuals is most
often the result of reactivation of latent infection, which
presents neurological signs, including headache, disorientation,
drowsiness, hemiparesis, reflex changes, and convulsions (Barratt
et al., 2010; Robert-Gangneux and Darde, 2012). Acute acquired
T. gondii infection in immunocompromised patients may also
occur and involvemultiple organs. Pneumonia, retinochoroiditis,
and other disseminated systemic diseases, can also be seen, but
are not as common as encephalitis in immunocompromised
patients (Machala et al., 2015).
An increased frequency of Toxoplasma encephalitis has been
reported in AIDS patients, especially those with significant
immunosuppression when CD4 T lymphocyte cell counts is
<200 cells/µL, and T. gondii infection is regarded as an
important opportunistic pathogen that lead to the death of
AIDS patients (Luft et al., 1993; Jones et al., 1996). The
cancer can also reactivate latent T. gondii infection during
antitumor treatment process (Frenkel et al., 1978). A variety
of malignancies, including lymphoma, leukemia, and myeloma,
can reactivate toxoplasmosis (Maciel et al., 2000; Kojima et al.,
2010). Transplantation of an organ from seropositive donor can
activate latent infection in a seronegative recipient receiving
immunotherapy (Chehrazi-Raﬄe et al., 2015). Transplantation of
an organ from seronegative donor can also initiate fatal infection
by activation of the latent infection in a seropositive recipient
receiving immunosuppressive therapy. It seems that danger of
transplanting an infected organ into a seronegative recipient
is greater than that of transplanting a non-infected organ into
a seropositive recipient (Chehrazi-Raﬄe et al., 2015). Fatal
toxoplasmosis has been reported in heart, liver and bonemarrow,
haematopoietic stem cell transplant recipients (Castagnini et al.,
2007; Caner et al., 2008; Stajner et al., 2013; Gajurel et al., 2015).
Toxoplasmosis can be complicated and is considered a
serious disease in immunocompromised patients, in which the
reactivation of a latent infection can be fatal. The incidence
of reactivated toxoplasmosis may rely on the prevalence and
concentration of IgG antibodies (Robert-Gangneux and Darde,
2012). It is necessary to obtain information concerning the
prevalence of T. gondii infection in different special populations
worldwide. We conducted a global meta-analysis to assess the
seroprevalence and odds ratios (ORs) of T. gondii infection in
immunocompromised patients compared with those in control
individuals.
MATERIALS AND METHODS
Search Strategy and Selection Criteria
We reported this meta-analysis in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) statement (Moher et al., 2009). We
searched PubMed, Embase, Google scholar, ScienceDirect,
Chinese Web of Knowledge, Wanfang, and Chongqing VIP
databases from inception to February 29, 2016, for all reports
that possibly contained data for T. gondii prevalence in
different immunocompromised populations. The databases
were searched using the keywords “Toxoplasma gondii”
and “toxoplasmosis” cross-referenced with “HIV,” “AIDS,”
“acquired immune deficiency syndrome”, “cancer,” “tumor,”
“malignancy,” “carcinoma,” “transplantation,” “organ grafting,”
“immunodeficiency,” and “immune deficiency.” We included
studies without language limitation.
We systematically searched the scientific literatures for
case-control, cohort, and cross-sectional studies that reported
T. gondii infection in immunocompromised individuals,
stratified by one of the following criteria: population with
HIV/AIDS or without HIV/AIDS; population with cancer or
without cancer; transplant or non-transplant population. Studies
were excluded if they were reviews, repeated studies, or animal
studies. Studies were excluded if they provided the final result
without raw data. Studies were excluded if the sample size from
one of the two groups was <30.
All identified titles and abstracts were carefully examined
by two independent reviewers (HHL and HYM). The full text
of articles considered as potentially relevant based on title
and abstract were independently examined by the same two
reviewers. Any disagreements with the selected studies were
resolved by discussion and the involvement of another two
authors (ZDW and QL).
Data Extraction and Quality Assessment
The following information was extracted from each study: first
author, publication year, country of the study, the number
of patients and control, diagnostic methods, and demographic
characteristics. Two reviewers (ZDW and YZL) independently
extracted the data and reached a consensus after a discussion on
the controversial literatures.
The quality of the included publications was assessed based
on the criteria (Liu et al., 2009; Speich et al., 2016). These
criteria were created based on the Grading of Recommendations
Assessment, Development and Evaluation method (Atkins et al.,
2004), and including the diagnostic approach of T. gondii
infection and matching of case and control subjects (Table 1).
A scoring approach was used for grading, and up to 11 points
assigned to each study. Studies that were awarded 6–11 points
were considered to be of high quality, 4–5 points were moderate
quality, whereas lower scores indicated low quality.
Statistical Analysis
We estimated prevalence of T. gondii infection by pooling of data
from each study. Data were pooled with a DerSimonian-Laird
random-effects model (DerSimonian and Laird, 1986; Borenstein
et al., 2010), whose difference was compared usingWilcoxon two-
sample test or t-test. The risk of T. gondii infection in patient
and control groups was estimated by odds ratio (OR). It was
considered statistically significant when p < 0.05. In the forest
plots,OR> 1 showed a risk effect andOR< 1 showed a protective
effect. Statistical heterogeneity of results was appraised using a
x2-basedQ-test and I2 statistic. The heterogeneity was considered
not significant only when p > 0.1 and I2 < 50%. The fixed-
effects model was used when literature heterogeneity not existed;
otherwise, the random-effects model was employed. Sensitivity
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TABLE 1 | Quality criteria for the included studies.
Quality
parameter
Score
2 1 0
Diagnostic
approach
– Approach clearly described nd
– Repeatedly examined by a
test or two different tests
nd
– Re-examined by a senior
laboratory technician
nd
Study design Cohort study Case control study or cross
sectional study
–
No. of case
subjects
≥100 50–100 ≤50
Source of
population
Community-based
or from two or more
countries
≥2 hospitals 1 hospital
Matching of
case and control
subjects
Age and sex Age or sex nd
nd, no data available.
analysis was performed by modification of the inclusion criteria
of this meta-analysis. The analysis was conducted using Stata
software version 12.0 (Stata Corporation, College Station, TX,
USA). The publication bias was considered significant when
p-value of Begg’s test and Egger’s test was <0.05.
RESULTS
Literature Search
As shown in Figure 1, the literature search yielded 11,799
relevant studies, which included 2,434 duplicates. After a
careful examination of each article’s title and abstract, 493 were
considered as having potential value, and the full texts were
retrieved for detailed evaluation. A total of 422 potentially
relevant articles were excluded from this meta-analysis after
consulting the full text. Of these, 273 articles did not present
sufficient data that required, or not conform with the included
criteria; 135 had prevalence without raw data; 9 had unmatched
control populations; the sample size in three articles was <30;
there were two publications whose full texts were not retrieved.
One additional publication regarding T. gondii infection in HIV
patients was identified through the second search on Feb, 29,
2016. Finally, a total of 72 publications were included for our
meta-analyses.
Characteristics of Included Studies
Characteristics of the included publications are listed in
Tables 2–4. In brief, 38 publications described T. gondii infection
in HIV/AIDS patients, 28 articles investigated T. gondii infection
in cancer patients, whereas 6 studies reported T. gondii
infection in transplant patients. The identified studies were
conducted worldwide (Figure 2). In terms of epidemiological
design, 51 of the included publications were case-control studies,
17 were cross-sectional studies, and four were cohort studies.
Thirty-nine papers were written in English, 29 were in Chinese,
FIGURE 1 | Data search and selection.
two in French (Maiga et al., 2001; Gamba et al., 2013), and one
each in Spanish (Gongora-Biachi et al., 1998) and in Croatian
(Dakovic-Rode et al., 2010). There were 6 papers whose raw data
were extracted from the abstract (Ryan et al., 1993; Gongora-
Biachi et al., 1998; Sukthana et al., 2000; Uneke et al., 2005;
Akanmu et al., 2010; Manouchehri Naeini et al., 2015). The oldest
study was conducted in 1987 (Quinn et al., 1987). Totally, 40
datasets investigated T. gondii infection in HIV/AIDS patients,
and 29 datasets examined T. gondii infection in cancer patients,
whereas only six datasets studied T. gondii infection in transplant
recipients.
According to our criteria, eight publications were of high
quality (>6 points), 43 publications had quality scores of 4–6
points indicating moderate quality, whereas the remaining 21
publications were of low quality (<4 points).
Pooled Prevalence of T. gondii Infection
(IgG) in Immunocomprised Patients
The estimated pooled prevalence of T. gondii infection in the
HIV/AIDS patients and control population was 42.1% (95%
CI, 34.0–50.2%) and 32.0% (95% CI, 24.0–40.1%), respectively
(p < 0.05); the prevalence in cancer patients and control was
26.0% (95% CI, 20.5–31.5%) and 12.1% (95% CI, 9.5–14.8%),
respectively (p < 0.001); and the prevalence in transplant
recipients and its control was 42.1% (95% CI, 27.1–57.2%) and
34.5% (95% CI, 17.1–51.9%), respectively (p = 0.59). The results
are shown in Supplementary Figures 1–6.
Association of Immunocomprised Patients
with T. gondii Infection
Forest plots on the association of immunosuppressed
populations withT. gondii infection are presented in Figures 3–5.
The estimated pooled random effects ORs of HIV/AIDS, cancer,
and transplant patients compared with their controls were
1.92 (95% CI, 1.44–2.55), 2.89 (95% CI, 2.36–3.55), and 1.51
(95% CI, 1.16–1.95) for infection with T. gondii. However, the
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TABLE 2 | Characteristics of the included studies forT. gondii infection
(IgG) in HIV/AIDS patients.
References Study
design
Country Study
population
Method Score
Quinn et al., 1987 C-C DR Congo NA IFA 3
Quinn et al., 1987 C-C USA Homosexual
men
IFA 4
Zumla et al., 1991 C-C Uganda NA DT, LAT 6
Zumla et al., 1991 C-C Zambia NA DT, LAT 6
Meisheri et al., 1997 C-C India NA ELISA 2
Wongkamchai et al.,
1995
C-C Thailand NA ELISA 1
Gongora-Biachi
et al., 1998
C-C Mexico NA MEIA 4
Chaves-Borges
et al., 1999
C-S India NA ELISA 4
Sukthana et al.,
2000
C-C Thailand NA NA 3
Praharaj et al., 2001 C-C India NA ELISA 7
Wanachiwanawin
et al., 2001
C-C Thailand Pregnant
women
ELISA 4
Maiga et al., 2001 C-C Mali NA ELISA 5
Zhou and Huang,
2001
C-C China NA MEIA 3
Falusi et al., 2002 C-S USA NA DT 5
Nissapatorn et al.,
2002
C-S Malaysia NA ELISA 4
Uneke et al., 2005 C-C Nigeria NA ELISA 4
Simpore et al., 2006 C-S Burkina
Faso
Pregnant
women
ELISA 3
Jin et al., 2006 C-S China Drug user ELISA 3
Shimelis et al., 2009 C-C Ethiopia NA ELISA 5
Ouermi et al., 2009 C-C Burkina
Faso
Pregnant
women
ELISA 5
Hua et al., 2009 C-C China NA ELISA 3
Lago et al., 2009 C-S Brazil Pregnant
women
ELFA 4
Akanmu et al., 2010 C-C Nigeria NA ELISA 4
Li et al., 2010 C-S China Drug
users
ELISA 3
Sitoe et al., 2010 C-C Mozambique Pregnant
women
ELISA 4
Tian et al., 2010 C-C China NA ELISA 6
Dakovic-Rode et al.,
2010
C-C Croatia NA ELISA 4
Daryani et al., 2011 C-S Iran NA ELISA 4
Fernandes et al.,
2012
C-C Brazil Pregnant
women
ELFA 3
Song, 2012 C-S China NA ELISA 5
John et al., 2012 C-C Papua
NewGuinea
NA ELISA 7
Alavi et al., 2013 C-C Iran Drug user ELISA 2
Gamba et al., 2013 C-C Central
Africa
Pregnant
women
ELISA 5
You, 2013 C-C China NA ELISA 7
Ogoina et al., 2013 C-S Nigeria NA ELISA 3
(Continued)
TABLE 2 | Continued
References Study
design
Country Study
population
Method Score
Walle et al., 2013 C-S Ethiopia NA ELISA 5
Endris et al., 2014 C-S Ethiopia NA ELISA 2
Pang et al., 2015 C-S China NA ELISA 3
Uppal et al., 2015 C-S India NA ELISA 4
Shen et al., 2016 C-C China NA ELISA 3
HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; C-
C, case control study; C-S, cross-sectional study; NA, not applicable because the
reference does not provide this parameter; IFA, indirect fluorescent antibody test; MEIA,
microparticle enzyme immunoassay; DT, dye test; LAT, latex agglutination test; ELISA,
enzyme-linked immunosbsorbent assay.
heterogeneity analysis showed that there was a relatively high-
level heterogeneity in our meta-analysis of HIV/AID patients
(Q = 401.6, I2 = 90.3%, p = 0.000) and cancer individuals
(Q = 76.4, I2 = 63.4%, p = 0.000), and no heterogeneity
was found in transplant recipients (Q = 8.0, I2 = 37.3%,
p= 0.157).
We also analyzed all the data, showing that the estimated
pooled prevalence of T. gondii infection in immunocompromised
patients and the controls was 35.9% (95% CI, 31.0–40.8%) and
24.7% (95% CI, 20.5–28.8%, p < 0.001), with an OR of 2.24 (95%
CI, 1.87–2.69).
Subgroup Analysis
All subgroup analysis, including those of geographical
distribution, country income, published years, sample size,
detection methods, study design, and population, did not
show any significant differences between the respective groups,
as indicated by overlapping 95% CIs, with the exception of
subgroups based on geographical distribution and income level
(Supplementary Table 1). For example, the odd of T. gondii
infection in HIV/AIDS patients in Asia (OR = 2.77, 95% CI,
1.58–4.87) was significantly higher as comparison with that in
Latin America (OR = 1.19, 95% CI, 0.90–1.56) and in Europe
(OR = 0.97, 95% CI, 0.65–1.46); the odd of T. gondii infection
in cancer patients in Asia (OR = 3.07, 95% CI, 2.51–3.76) was
significantly higher, compared with that in Oceania (OR = 1.42,
95% CI, 0.80–2.54). Additionally, higher odds of T. gondii
infection in both HIV/AIDS and cancer patients were found in
middle-income and low-income countries, compared with that
of high-income countries.
Publication Bias and Sensitivity Analysis
Begg and Egger tests were used to evaluate the publication bias.
No significant bias was revealed in HIV/AIDS- or transplant-
related publications, but significant bias was observed in cancer-
associated publications (p < 0.05, Supplementary Table 1,
Supplementary Figure 7).
A sensitivity analysis was conducted by excluding one single
study each time to find out whether modification of the inclusion
criteria of this meta-analysis had an effect on the final results. All
the results were not materially altered (data not shown).
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TABLE 3 | Characteristics of the included studies for cancer patients.
References Study
design
Country Cancer Control Method Score
Wei et al., 1991 C-C China Mixed NP IHA,
ELISA
4
Zhao et al., 1992 C-C China Mixed NP ELISA 2
Ryan et al., 1993 C-C Australia Glioma NP ELISA 4
Ryan et al., 1993 C-C Australia Meningioma NP ELISA 4
Peng et al., 1994 C-C China Mixed NP IHA 4
Wu et al., 1994 C-C China Mixed NP IHA 5
Lai et al., 1998 C-C China Mixed NP ELISA 5
Liu and Li, 1998 C-C China Mixed NP IHA 3
Zhang et al.,
1998
C-S China Mixed NP IHA 5
Wang et al., 2000 C-C China Mixed NP ELISA 6
Huang et al.,
2000
C-C China Cervical
cancer
Other
diseases
ELISA 3
Wu et al., 2000 C-C China Mixed NP IHA,
ELISA
5
Wei and Zhu,
2000
C-C China Mixed NP ELISA 3
Yang et al., 2001 C-C China Mixed NP ELISA 4
Zhang et al.,
2003
C-C China Mixed NP ELISA 3
Yazar et al., 2004 C-C Turkey Mixed NP ELISA 7
Huang et al.,
2005
C-C China Mixed NP IHA 5
Ma et al., 2006 C-C China Mixed NP ELISA 3
Zheng et al.,
2006
C-C China Lung
cancer
NP ELISA 5
Yuan et al., 2007 C-C China Mixed NP ELISA 4
Ghasemian et al.,
2007
C-S Iran Mixed NP ELISA 7
Sun et al., 2008 C-C China Mixed NP ELISA 4
Li et al., 2008 C-C China Mixed NP ICT 4
Zhang et al.,
2009
C-C China Mixed NP ELISA 3
Lian et al., 2010 C-C China Mixed NP ELISA 4
Cong et al., 2015 C-C China Mixed NP ELISA 8
Tian et al., 2015 C-C China Leukemia
and
Lymphoma
NP ELISA 3
Manouchehri
Naeini et al., 2015
C-C Iran Mixed NP ELISA 7
Kalantari et al.,
2015
C-S Iran Breast
cancer
Healthy
women
ELISA 6
C-C, case-control study; C-S, cross-sectional study; IHA, indirect hemagglutination;
ELISA, enzyme-linked immunosbsorbent assay; ICT, immunochromatographic test; NP,
normal population.
Pooled Prevalence of T. gondii Infection
(IgM) in Immunocomprised Patients
Our meta-analysis focused on T. gondii IgG antibodies, which
are a marker of lifetime exposure to toxoplasmosis, whereas
IgM antibodies are a marker of acute or recent infection,
or also potentially persistent infection or reinfection with a
TABLE 4 | Characteristics of the included studies for transplant recipients.
References Study
design
Country Control
population
Transplanted
organ
Method Score
Sluiters et al., 1989 C Netherland Donor Heart ELISA 5
Gan et al., 1991 C-C China Self-control Kidney IHA 4
Arora et al., 2007 C Norway Donor Heart ELISA 5
Caner et al., 2008 C Turkey Donor Liver DT 5
Gharavi et al., 2011 C Iran Self-control Kidney ELFA,
ELISA
9
Gharavi et al., 2011 C Iran Self-control Kidney ELISA 9
Soltani et al., 2013 C-S Iran Healthy
subjects
Kidney ELISA 4
C, cohort study; C-C, case-control study; C-S, cross-sectional study; IHA, indirect
hemagglutination; DT, dye test; LAT, latex agglutination test; ELFA, enzyme-linked
flourescence assay; ELISA, enzyme-linked immunosorbent assay.
different genotype (Sharma et al., 1983; Dzitko et al., 2006).
During extraction of data in this study, the IgM antibodies
against T. gondii in immunocompromised patients were also
collected (Supplementary Tables 2–4). Due to insufficient data
on HIV/AIDS and transplant patients, we only analyzed T. gondii
IgM in cancer patients and the control, showing a prevalence of
11.4% (95% CI, 8.1–14.7%) in cancer patients and 2.7% (95%
CI, 1.5–4.0%, p < 0.01) in its control group and OR of 2.65
(95% CI, 2.04–3.45, Supplementary Figures 8–10). The results
also confirmed that the immunocompromised patients were
associated with significantly higher odds of recently acquired
T. gondii infection.
DISCUSSION
T. gondii has been suggested as an important opportunistic
pathogen in immunocompromised patients (Walker and Zunt,
2005). The infection in healthy (immunocompetent) people
is usually self-limited and asymptomatic, resulting in chronic
infection of tissue cysts that can lie dormant, probably for the
entire lifetime of the hosts. However, immunocompromised
individuals, such as HIV/ADIS patients, cancer patients
with chemotherapy, and transplant recipients, are at risk
of developing Toxoplasma encephalitis, myocarditis, or
pneumonitis, due to reactivation of the chronic infection.
For example, approximately 30–40% of HIV co-infected
immunocompromised individuals with T. gondii develop
encephalitis (Walker and Zunt, 2005).
The associations of HIV and seroprevalence of T. gondii
infection are varied in the world (Grant et al., 1990). Some
reports showed higher prevalence of T. gondii infection in HIV-
infected patients compared to non-infected individuals, whereas
others did not find any differences between the two groups
(Sukthana et al., 2000; Galvan-Ramirez Mde et al., 2012). This
global systematic review and meta-analyses were conducted
to quantify the prevalence and ORs of T. gondii infection
in immunocompromised individuals compared with those in
control individuals.
Subgroup analyses comparing published year, sample size,
detection method, study design, country income, and population
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FIGURE 2 | Geographical distribution of the included studies. The map was created using MapInfo Professional software version 9.5. Pooled odds ratio and
95% confidence interval are shown for each country.
FIGURE 3 | Meta-analysis of the association of HIV/AIDS patients and T. gondii infection (IgG) with random-effects analysis. CI, confidence interval; OR,
odds ratio.
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FIGURE 4 | Meta-analysis of the association of cancer patients and T. gondii infection (IgG) with random-effects analysis. CI, confidence interval; OR,
odds ratio.
FIGURE 5 | Meta-analysis of the association of transplant recipients and T. gondii infection (IgG) with fixed-effects analysis. CI, confidence interval; OR,
odds ratio.
revealed non-significant differences, but high odds were found
for T. gondii infection in HIV/AIDS patients in Asia and
Africa as comparison with that of America and Europe, and
in cancer patients in Asia compared to that in Oceania
(Supplementary Table 1). However, only one or two studies
examined the association of immunocompromised patients with
T. gondii infection in these regions. Thus, no meta-analysis could
be done and no firm conclusion should be drawn. Most studies
were conducted in the countries of Asia. Our analyses further
demonstrated that the studies are geographically clustered,
with few studies in Latin America, Europe, and Oceania
(Figure 2).
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The presence of heterogeneity was observed in HIV/AIDS and
cancer patients, but subgroup analyses did not explain the specific
causes of heterogeneity, which may come from various sources,
including geographical distribution, published years, sample size,
detection methods, study design, or populations. Without meta-
regression or additional subgroup analysis that requires a large
number of studies, it is difficult to investigate the causes of
heterogeneity. The presence of heterogeneity shows that pooled
results are averaging multiple related, but different effects (Strunz
et al., 2014).
In fact, higher prevalence of T. gondii infection in HIV/AIDS
patients has been reported in many countries, such as Nigeria,
Mali, Ethopia, India, China, and Thailand (Maiga et al., 2001;
Wanachiwanawin et al., 2001; Akanmu et al., 2010; Daryani
et al., 2011; Uppal et al., 2015; Shen et al., 2016). The present
study provided robust evidence that support the conclusion, and
demonstrated that HIV/AIDS patients are associated risk factors
(OR = 1.92, 95% CI 1.44–2.55) for T. gondii infection. The data
were derived from 38 publications from 20 countries, which
included 10,028 HIV/AIDS patients and 12,334 control people
(Table 2).
A recent study reported T. gondii infection in Chinese cancer
population, with a prevalence of 20.6% in cancer patients and
6.3% in the control (OR = 3.9) (Jiang et al., 2015). Our meta-
analysis also included the data of other countries, such as
Australia, Iran, and Turkey (Table 3), which involved 7,011
cancer patients and 9,254 control people, therefore, the results
would bemore reliable. However, of the included 28 publications,
21 were written in Chinese, resulting in significant publication
bias.
There are many case reports of toxoplasmosis in transplant
recipients, including haematopoietic cell (Barcan et al., 2002),
heart (Gajurel et al., 2015), liver (Hamza et al., 2015), and
kidney (Petty et al., 2015) transplant patients. A previous
study reported a higher prevalence of T. gondii infection
in renal transplant recipients (Soltani et al., 2013). In the
present study, we analyzed T. gondii infection in 671 transplant
patients (heart, kidney, and liver) and 628 control people from
five countries (Table 4), revealing no significant difference of
T. gondii infection between the two groups, but showing that
transplant population is an risk factor (OR= 1.51, 95% CI, 1.16–
1.95) for T. gondii infection. Interestingly, it was found that 14.3%
of renal transplant recipients were detected positive for T. gondii
infection in the first year of transplantation, and the prevalence
increased to 85.7% in 1 year post-transplantation (Aufy et al.,
2009).
There are several limitations in this meta-analysis, which may
affect the results. First, a number of potentially relevant studies
were identified through our systematic review, but not all the
underlying data were available. Therefore, though most of these
studies might not have relevant data, there is a certain risk to miss
some eligible data.
Second, based on our scoring system, most studies were of
moderate or even relatively low quality. This finding is mainly
due to the epidemiological design of the studies; most were cross-
sectional in nature. The differences between the study groups also
included ages, lifestyles, and geographical conditions, which all
contribute to the difference of T. gondii infection between the
patient and control groups (Minbaeva et al., 2013; Walle et al.,
2013; Wang et al., 2015). The cluster randomized controlled trial
would provide high-quality data, but their implementation is
more difficult. An alternative way to generate high-quality data
would be using a time-series approach as a study design (Speich
et al., 2016).
Third, diagnosis of T. gondii infection in
immunocompromised patients is difficult. Though detection
of the parasite by microscopy and bioassays is considered as
the gold standard for diagnosis of toxoplasmosis, its clinical
diagnosis more likely relies on serological methods (Liu et al.,
2015). However, the serological methods may be unreliable in
the immunocompromised individuals, whose immune system
has been impaired, and cannot produce enough antibodies
(Lewis et al., 2015). In the identified studies, all the detection
methods were serological, including indirect hemagglutination
(IHA), dye test (DT), immunochromatographic test (ICT), and
enzyme-linked immunosorbent assay (ELISA) (Tables 2–4).
Thus, by the reason of lack of specific antibody, the
detected results would be lower than the actual prevalence
in immunocompromised patients, including HIV/AIDS patients,
cancer patients, and transplant recipients (Saadatnia and Golkar,
2012).
Fourth, insufficient data about further relevant factors on
T. gondii infection (e.g., age, cancer type, transplanted organ)
were available for subgroup analysis.
In summary, our global meta-analysis shows a higher
prevalence of T. gondii infection in immunocompromised
patients, and demonstrates that the immunocompromised
individuals, including HIV/AIDS patients, cancer patients, and
transplant recipients, were associated with higher odds of
T. gondii infection. Therefore, a routine serological screening
test for T. gondii infection is suggested to be conducted in
immunocompromised patients in endemic area, or patients with
no proper chemoprophylaxis and/or HAART. Patients with
a positive result are at risk of reactivation of the infection,
while patients with a negative result should be informed to
prevent primary infection. Health education, particularly toward
avoiding eating raw and undercookedmeat, and avoiding contact
with cats’ feces should also be considered.
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